Glenn Rosen, MD
Family Medicine · Philadelphia, PANPI 1629115340
Payments from drug & device makers
Across 1,563 payments — averaging $234.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$299K
- AbbVie$24K
- Idorsia Pharmaceuticals US Inc$17K
- Eli Lilly$7K
- GSK$4K
- Pfizer$2K
- plus $14K from 44 others
Across 1 payment — averaging $1126.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$1K
What the payments were for
- Consulting fees$11,98520%
- Speaking & faculty fees$27,22644%
- Travel & lodging$2,3474%
- Food & beverage$19,56332%
- Education$2370%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QUVIVIQ$16,911
- UBRELVY$12,482
- VRAYLAR$3,025
- BOTOX$2,993
- NUCALA$2,411
- QULIPTA$1,875
- COLOGUARD$1,250
- FREESTYLE LIBRE 3$487
- TRELEGY ELLIPTA$473
- XEOMIN$444
- Cologuard Collection Kit$248
- TRULANCE$123
- AREXVY$122
- The Cologuard Plus Collection Kit$113
- AIRSUPRA$102
How this compares
$366,940 in reported general payments places this provider in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 171 | $186,245 |
| JardianceEmpagliflozin | 188 | $161,673 |
| OzempicSemaglutide | 133 | $148,055 |
| EliquisApixaban | 143 | $126,037 |
| FarxigaDapagliflozin Propanediol | 88 | $88,606 |
| EntrestoSacubitril/Valsartan | 63 | $58,774 |
| MounjaroTirzepatide | 25 | $40,770 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $38,616 |
| LinzessLinaclotide | 55 | $34,079 |
| PrezcobixDarunavir/Cobicistat | 14 | $33,907 |
| MyrbetriqMirabegron | 48 | $31,973 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $28,506 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $28,168 |
| JanuviaSitagliptin Phosphate | 28 | $25,222 |
| XareltoRivaroxaban | 32 | $17,518 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $1,360 | $227,015196 claims |
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus | $1,568 | $174,979157 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $878 | $172,879204 claims |
| PfizerEliquis | $1,725 | $126,037143 claims |
| AstraZenecaFarxiga, Symbicort | $1,339 | $97,165114 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $4,057 | $83,101151 claims |
| NovartisEntresto | $202 | $58,77463 claims |
| Johnson & JohnsonPrezcobix, Xarelto | $339 | $51,42446 claims |
| Astellas Pharma US IncMyrbetriq, Veozah | $526 | $41,08765 claims |
| AbbVieLinzess | $24,135 | $34,07955 claims |
| GileadDescovy | $586 | $28,16813 claims |
| MerckJanuvia | $627 | $25,22228 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Daniel LinPhiladelphia$392K
- Christopher ChambersPhiladelphia$350K
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.